Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · Real-Time Price · USD
11.39
-0.04 (-0.35%)
Nov 28, 2025, 11:26 AM EST - Market open
Dynavax Technologies Revenue
Dynavax Technologies had revenue of $94.88M in the quarter ending September 30, 2025, with 17.67% growth. This brings the company's revenue in the last twelve months to $330.51M, up 26.73% year-over-year. In the year 2024, Dynavax Technologies had annual revenue of $277.25M with 19.36% growth.
Revenue (ttm)
$330.51M
Revenue Growth
+26.73%
P/S Ratio
4.23
Revenue / Employee
$816,084
Employees
405
Market Cap
1.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 277.25M | 44.96M | 19.36% |
| Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
| Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
| Dec 31, 2021 | 439.44M | 399.19M | 991.75% |
| Dec 31, 2020 | 40.25M | 5.03M | 14.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DVAX News
- 8 days ago - Dynavax to Participate at the 8th Annual Evercore Healthcare Conference - PRNewsWire
- 22 days ago - Dynavax Technologies Corporation (DVAX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program - PRNewsWire
- 22 days ago - Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program - PRNewsWire
- 5 weeks ago - Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025 - PRNewsWire
- 5 weeks ago - Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial - PRNewsWire
- 2 months ago - 3 Of My Favorite Biotech Stocks Under $10 - Seeking Alpha
- 3 months ago - Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference - PRNewsWire